Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some clinically relevant claims align with the provided label (e.g., indication and basic single-patient-use/discard after dosing instructions). However, multiple claims about expiration dates, shelf-life/EXPs, exclusivity/patent-expiry/generic launch timing, and opened-container/discard-after-opening instructions are not supported by the provided label excerpts and appear to conflate regulatory exclusivity with product expiration. Several label-relevant points (like discard immediately after administration from a single patient-use container) are directionally different from the claim about “discard after opening.”
Category Scores
Accurate Statements
Upneeq is (oxymetazoline hydrochloride) ophthalmic solution used to treat certain eyelid conditions.
Label Indications/Usage: “UPNEEQ is indicated for the treatment of acquired blepharoptosis in adults.”
If the Upneeq product has been opened, the “discard after opening” instruction on the label should be followed if one is printed.
Label Dosage/Administration: “Instill one drop of UPNEEQ into one or both ptotic eye(s) once daily. Discard the single patient-use container immediately after dosing.”
Unsupported Statements
The expiration date for Upneeq can refer to the labeled shelf-life on the bottle.
No expiration/shelf-life labeling language was provided in the supplied label excerpts.
The expiration date for Upneeq can refer to regulatory/market exclusivity or patent-expiry dates that determine when generic or competing products may enter.
No information in the supplied label excerpts connects “expiration date” to regulatory/market exclusivity or patent-expiry for generics/competitors.
Upneeq expiration information can be found on the carton or label as an “EXP,” “Expiration,” or “Use by” date.
No label excerpt provided describing how expiration dates are printed/abbreviated (e.g., EXP/Use by).
The label for Upneeq may include instructions for storage and whether it provides guidance for an “opened” or “discard after” time period.
No storage or opened/discard-after time period content was provided in the supplied excerpts.
When Upneeq’s patent/exclusivity ends, generics or authorized competitors may be able to launch.
No patent/exclusivity or generic launch timing language is present in the supplied label excerpts.
Upneeq patent and exclusivity dates are tied to specific patents covering the drug/product and any exclusivity periods granted by regulators.
No such patent/exclusivity detail is provided in the supplied label excerpts.
Patent/exclusivity end dates can differ from the medication’s shelf-life date.
No shelf-life or patent/exclusivity end-date discussion is provided in the supplied label excerpts.
Patent/exclusivity end dates can differ from the date when a generic is first allowed to file or market.
No generic filing/marketing authorization timing language is provided in the supplied label excerpts.
Patent/exclusivity end dates can differ from the date competitors actually launch.
No competitor launch timing language is provided in the supplied label excerpts.
Expiration dates for Upneeq are product- and packaging-specific.
No expiration-date packaging/product specificity language is provided in the supplied label excerpts.
Contradictions
Low
AI Statement
If the Upneeq product has been opened, the “discard after opening” instruction on the label should be followed if one is printed.
Label Reference
Label Dosage/Administration: “Discard the single patient-use container immediately after dosing.” and Patient Counseling: “the solution from one single patient-use container is to be used immediately after opening… discarded immediately after administration.”
Important Omissions
No mention that UPNEEQ uses single patient-use containers and the solution should be used immediately after opening and discarded immediately after administration/dosing (label does not describe a time-based “discard after opening” period for containers).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The main safety-relevant label instruction provided is to discard the single patient-use container immediately after dosing/administration. The AI claim frames a potentially time-based “discard after opening” approach (if printed), which is not supported by the provided excerpts and could be misinterpreted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Expiration/patent/exclusivity and generic/competitor launch timing claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to what the label excerpt supports (e.g., indication and single patient-use discard immediately after dosing/administration). Remove or reframe statements about regulatory exclusivity/patent expiry/generic launch timing and about generic storage/“discard after opening” time periods unless the exact label text is provided.